Department of Translational Medical Sciences, University of Campania 'L. Vanvitelli', Naples, Italy.
Department of Renal Medicine, University College London, London, UK.
Nephrol Dial Transplant. 2021 Aug 27;36(9):1585-1596. doi: 10.1093/ndt/gfab171.
Distal renal tubular acidosis (dRTA) is characterized by an impaired ability of the distal tubule to excrete acid, leading to metabolic acidosis. Associated complications include bone disease, growth failure, urolithiasis and hypokalaemia. Due to its rarity, there is limited evidence to guide diagnosis and management; however, available data strongly suggest that metabolic control of the acidosis by alkali supplementation can halt or revert almost all complications. Despite this, cohort studies show that adequate metabolic control is present in only about half of patients, highlighting problems with treatment provision or adherence. With these clinical practice points the authors, part of the working groups tubulopathies in the European Rare Kidney Disease Reference network and inherited kidney diseases of the European Society for Paediatric Nephrology, aim to provide guidance for the management of patients with dRTA to facilitate adequate treatment and establish an initial best practice standard against which treatment of patients can be audited.
远端肾小管性酸中毒(dRTA)的特征是远端肾小管排酸能力受损,导致代谢性酸中毒。相关并发症包括骨骼疾病、生长发育迟缓、尿路结石和低钾血症。由于其罕见性,指导诊断和管理的证据有限;然而,现有数据强烈表明,通过碱补充来控制酸中毒的代谢可以阻止或逆转几乎所有的并发症。尽管如此,队列研究表明,只有大约一半的患者存在足够的代谢控制,这突出了治疗提供或依从性方面的问题。带着这些临床实践要点,作者们——欧洲罕见肾脏疾病参考网络的肾小管病工作组和欧洲儿科学会遗传性肾脏疾病工作组的一部分——旨在为 dRTA 患者的管理提供指导,以促进充分的治疗,并建立一个初始的最佳实践标准,据此可以对患者的治疗进行审核。